Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FYU-981 (Dotinurad) in Hepatic Insufficiency
NCT03306667Phase 1Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dotinurad in hyperuricemia and gout (4 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoints: Maximum plasma concentration at 48 hours, Time to reach peak plasma concentration at 48 hours and 6 more. Started Oct 2017; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT03306667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306667.